Related Experiment Video
Updated: Mar 14, 2026
09:57
A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
Published on: December 23, 2016
9.3K
Phenylboronic Acid-Cross-Linked Nanoparticles with Improved Stability as Dual Acid-Responsive Drug Carriers
Chunran Wang1, Jinze Wang1, Xiaofei Chen1
1Department of Chemistry, Northeast Normal University, Changchun, 130024, P. R. China.
Macromolecular Bioscience
|September 23, 2016
Summary
New dual acid-sensitive nanoparticles offer improved stability and drug delivery for cancer treatment. These nanoparticles efficiently load and release anticancer drugs specifically within tumor cells, enhancing therapeutic efficacy.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery Systems
Background:
- Developing effective drug delivery systems is crucial for cancer therapy.
- Stimuli-responsive nanoparticles offer targeted drug release mechanisms.
- Acid sensitivity is a key feature for targeting tumor microenvironments and intracellular compartments.
Purpose of the Study:
- To construct dual acid-sensitive nanoparticles for enhanced anticancer drug delivery.
- To investigate the stability, drug loading, and release characteristics of these nanoparticles.
- To evaluate the potential of these nanoparticles as drug carriers for cancer treatment.
Main Methods:
- Fabrication of dual acid-sensitive nanoparticles using monomethoxy poly(ethylene glycol)-imine-β-cyclodextrin cross-linked with phenylboronic acid.
- Characterization of nanoparticle size, stability, and morphology using dynamic light scattering and transmission electron microscopy.
- Assessment of drug loading efficiency and in vitro drug release profiles at different pH conditions (neutral, tumor extracellular, and endosomal).
- Evaluation of cellular uptake and antiproliferative effects on cancer cells.
Main Results:
- Successfully constructed stable, cross-linked nanoparticles with improved stability.
- Demonstrated efficient self-assembly and anticancer drug loading at neutral pH.
- Observed pH-dependent surface charge changes and enhanced cellular internalization at tumor extracellular pH (≈6.8).
- Confirmed rapid drug release in acidic endosomal compartments (≈5.3) due to boronate ester hydrolysis.
- Showcased significant inhibition of cellular proliferation in vitro.
Conclusions:
- The developed dual acid-sensitive nanoparticles exhibit excellent biocompatibility and stability.
- These nanoparticles efficiently load and deliver anticancer drugs specifically to tumor cells.
- The dual pH-responsive mechanism facilitates targeted drug release, enhancing anticancer efficacy.
- This nanoparticle platform presents a promising strategy for advanced cancer drug delivery.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
79
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79
01:24Modified-Release Drug Delivery Systems: Site-Targeted
70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
73
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
73
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
72
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
72
01:23Modified-Release Drug Delivery Systems: Classification
167
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
167
01:11Oral Drug Delivery Systems: Delayed-Release Systems
93
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
93